PathogenDx, a company that specializes in microarray technology, has expanded the reach of its patented multiplexed molecular testing technology, Dynamic Dimensional Detection (D3Array), beyond the cannabis and hemp sectors. The D3Array addresses the challenges microarray technology have suffered in prior generations as well as the gap that qPCR and next-generation sequencing (NGS) has created in multiplexing, performance, throughput and cost, to the clinical, food and agriculture sectors.
The D3Array features a flexible, open, lattice-like architecture that is rich with highly accessible target-probe binding sites. The benefit of this is the ability of amplicon targets to:
- Move easily through the 3D structure
- Locate target:probe binding sites
- Bind more easily with significantly reduced steric hindrance.
Consequently, the duplex pairing hybridization reaction is rapid at room temperature and delivers high sensitivity and specificity results to labs and their clients.
PathogenDx’s D3 Array is adaptable to high throughput 96-well plate processing from sample to answer. Using standard lab equipment and basic PCR lab-tech proficiency, the D3 Array features include:
- 3D cross-linked, flexible architecture
- Increased access to target:probe binding sites
- Solution-like target:probe binding interaction
- Room temperature hybridization
- High affinity
- Minimized non-specific surface crowding
- Increases fidelity to enable SNP level detection
For more information, visit https://pathogendx.com/science/.
